Phase 1 Trial of CAR T-Cell Drug for Pancreatic Cancer Doses First Patient – Immuno-Oncology News
Immuno-Oncology News |
Phase 1 Trial of CAR T-Cell Drug for Pancreatic Cancer Doses First Patient
Immuno-Oncology News The Phase 1 trial assessing Bellicum Pharmaceuticals' BPX-601, a CAR T-cell therapy against the prostate stem cell antigen (PSCA), in inoperable pancreatic cancer has dosed its first patient. The company says this is the first CAR T-cell therapy aimed … |
